Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Advanced Triple-Negative Breast Cancer
NCT00371254Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2006
- Primary completion
- Sep 2008
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 2, open-label trial of dasatinib in triple-negative breast cancer (TNBC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Complete Response (CR) or Partial Response (PR) up to 65 weeks and Percentage of Participants With Complete Response (CR) or Partial Response (PR) up to 65 weeks. Started Dec 2006; status: completed.
02
Drugs
dasatinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00371254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00371254.